Stock Story -
Personal care company Nu Skin (NYSE:NUS) fell short of the market’s revenue expectations in Q3 CY2024, with sales falling 13.8% year on year to $430.1 million. Next (LON:NXT) quarter’s revenue guidance of $427.5 million underwhelmed, coming in 6.2% below analysts’ estimates. Its non-GAAP profit of $0.17 per share was also 13.5% below analysts’ consensus estimates.
Is now the time to buy Nu Skin? Find out by reading the original article on StockStory, it’s free.
Nu Skin (NUS) Q3 CY2024 Highlights:
- Revenue: $430.1 million vs analyst estimates of $441 million (2.5% miss)
- Adjusted EPS: $0.17 vs analyst expectations of $0.20 (13.5% miss)
- Revenue Guidance for Q4 CY2024 is $427.5 million at the midpoint, below analyst estimates of $455.8 million
- Management lowered its full-year Adjusted EPS guidance to $0.70 at the midpoint, a 17.6% decrease
- Gross Margin (GAAP): 70.1%, up from 58.6% in the same quarter last year
- Operating Margin: 4.2%, up from -5.3% in the same quarter last year
- Market Capitalization: $322.1 million
Company OverviewWith person-to-person marketing and sales rather than selling through retail stores, Nu Skin (NYSE:NUS) is a personal care and dietary supplements company that engages in direct selling.
Personal Care
While personal care products products may seem more discretionary than food, consumers tend to maintain or even boost their spending on the category during tough times. This phenomenon is known as "the lipstick effect" by economists, which states that consumers still want some semblance of affordable luxuries like beauty and wellness when the economy is sputtering.Consumer tastes are constantly changing, and personal care companies are currently responding to the public’s increased desire for ethically produced goods by featuring natural ingredients in their products.
Sales Growth
A company’s long-term performance is an indicator of its overall business quality. While any business can experience short-term success, top-performing ones enjoy sustained growth for multiple years.Nu Skin is a small consumer staples company, which sometimes brings disadvantages compared to larger competitors benefitting from economies of scale.
As you can see below, Nu Skin’s demand was weak over the last three years. Its sales fell by 13.8% annually, showing demand was weak. This is a rough starting point for our analysis.
This quarter, Nu Skin missed Wall Street’s estimates and reported a rather uninspiring 13.8% year-on-year revenue decline, generating $430.1 million of revenue. Management is currently guiding for a 12.5% year-on-year decline next quarter.
Looking further ahead, sell-side analysts expect revenue to remain flat over the next 12 months, an improvement versus the last three years. Although this projection shows the market believes its newer products will catalyze better performance, it is still below the sector average.
Cash Is King
Although earnings are undoubtedly valuable for assessing company performance, we believe cash is king because you can’t use accounting profits to pay the bills.Nu Skin has shown mediocre cash profitability over the last two years, giving the company limited opportunities to return capital to shareholders. Its free cash flow margin averaged 3.2%, subpar for a consumer staples business.